1 a Novartis company A Step-wise Approach for Leachables & Extractables Evaluation in pMDI Product Development Andrea Mieth Technical Development, Sandoz Development Center Rudolstadt, Germany IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31 st of March 2011 Agenda 1. Regulatory requirements 2. Step-wise approach according to PQRI guideline 3. Critical assessment of the packaging system 4. Case Study I: Controlled Extraction Study 5. Case Study II: Formulation development with DoE 6. Case Study III: Correlation of L&E 7. Conclusions
12
Embed
A Step-wise Approach for Leachables & Extractables ... · PDF fileA Step-wise Approach for Leachables & Extractables Evaluation in pMDI Product Development ... ICH guideline Q6A....
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
a Novartis company
A Step-wise Approach for Leachables & Extractables Evaluation in pMDI Product Development
Andrea MiethTechnical Development, Sandoz Development Center Rudolstadt, Germany
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011
Agenda
1. Regulatory requirements
2. Step-wise approach according to PQRI guideline
3. Critical assessment of the packaging system
4. Case Study I: Controlled Extraction Study
5. Case Study II: Formulation development with DoE
6. Case Study III: Correlation of L&E
7. Conclusions
2
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011
Regulatory Requirements
� Impurity guidelines
EMA guideline
Guideline on the limits of genotoxic impurities (TTC)
ICH guideline
Impurities in new drug substances (Q3A)
Impurities in new drug products (Q3B)
� EMA note for guidance
Note for guidance on specific limits for residues of metal catalysts or metal reagents
� ISO standard 10993
Biological evaluation of medical devices
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011
Regulatory Requirements
� FDA guidance
Container closure systems for packaging human drugs and biologics
� EMA guideline
Guideline on plastic immediate packaging
� ICH guideline Q8
Pharmaceutical development
� ICH guideline Q6A (Specifications)
Test procedures and acceptance criteria for new drug substances and
drug products
� PQRI leachables and extractables working group (recommendationsto the FDA)
Safety thresholds and best practices for extractables & leachables in orally
inhaled and nasal drugs
3
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011
Leachable and Extractable Testing
Step 1
Step 2
Step 5
Step 3
Step 4
CES (Controlled Extraction Study)
Correlation of L&E
Leachables study
Identification of L&E above AET
Critical assessment of the packaging system
� Step-wise approach according to PQRI recommendations:
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011
Step 1: Critical assessment of the packaging system
� Typical sources for L&E in pMDIs:
• Packaging
– Valve materials:
» Polypropylene (PP)
» Polybutylterephthalate (PBT)
» Polyoxymethylene (POM)
» Polychloroprene (PC)
» Ethylenepropylenediene monomer (EPDM)
» Polyamide (PA)
» Metals
» Lubricants
» …
– Can
» Coating material
» Metal
Gaskets
Stem
Spring
Body
Ring
• Typical leaching compounds
» Base material oligomers
» Antioxidants
» Processing aids
» Vulcanization agents
» Phthalates
» Fillers
» Metals
» …
4
IPAC RS 2011 | A. Mieth | Sandoz SDC Rudolstadt | 31st of March 2011